We have read with interest the recent article by Takahashi et al. 1 showing the changes in pancreatic a-cell function of a patient with fulminant type 1 diabetes. The pancreatic a-and b-cell functions were assessed by the arginine stimulation test. Thus far, no study has reported the time-course of changes in glucagon secretion in a patient with fulminant type 1 diabetes.
In recent-onset fulminant type 1 diabetes, a-cell mass should be decreased according to a previous study that reported a-cells, as well as b-cells, were morphologically damaged 2 . Takahashi et al. suggested the loss of a-cells in one case of fulminant type 1 diabetes. However, in our study participants with fulminant type 1 diabetes whose diabetes duration was >4 years, no defect in glucagon secretion was observed (Figure 1) . A physiological stimulus (mixed-meal) test tended to show rather excessive glucagon levels in the type 1A and fulminant type 1 diabetes patients compared with those of the healthy controls. Comparing among type 1 diabetes patients, the a-cell secretory capacity of fulminant type 1 diabetes seems marginally smaller than that of type 1A diabetes, but it can be said that certain amounts of acells do exist. a-Cells might be resistant to cytokine-induced apoptosis, which is postulated to be a mechanism of b-cell destruction in fulminant type 1 diabetes 3 . Type 1 diabetes is characterized by the selective loss of insulin-producing b-cells, which severely disturbs glucose homeostasis. It is also associated with dysfunction of the component of the a-cells, which can exacerbate hyperglycemia as a result of paradoxical hyperglucagonemia or lead to severe hypoglycemia as a consequence of impaired counterregulation. In accordance with this concept, we have previously showed that arginine-stimulated glucagon secretion is closely associated with the degree of glucose fluctuation in patients with type 1 diabetes whose endogenous insulin was completely depleted 4 . This research indicates that, independent of the lack of insulin secretion, the aberrant secretion of glucagon might contribute to glycemic variability.
Thus, a-cell behavior in fulminant type 1 diabetes needs to be urgently clarified when considering improving glycemic control in fulminant type 1 diabetes characterized by complete deficiency of insulin. Long-term longitudinal studies investigating a-cell function and its changes over time are required in the future. Figure 1 | Mixed-meal tolerance tests were carried out after an overnight fast. A liquid formula meal was used (Sanet-SAR; Sanwa Kagaku Kenkyusho, Nagoya, Japan; 6 kcal/kg bodyweight). Plasma glucagon was measured using a C-terminal-specific radioimmunoassay (Sceti Medical Labo, Tokyo, Japan). Meal-stimulated serum C-peptide levels were undetectable (<0.003 nmol/L) by a highly sensitive immunoradiometric assay kit (Roche, Basel, Switzerland) in all enrolled patients. Healthy control participants (■; n = 3, mean age 35.3 -6.1 years), type 1A diabetes patients (○; n = 6, mean age 57.7 -17.5 years, range 32-78 years, diabetes duration 14.2 -11.0 years, range 2-27 years) and fulminant type 1 diabetes patients (▲; n = 3, mean age 66.0 -13.0 years, range 51-73 years, diabetes duration 9.3 -5.5 years, range 4-15 years). Graphical data are presented as the mean -standard error of the mean. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
